Identification of new epitopes from four different tumor-associated antigens: Recognition of naturally processed epitopes correlates with HLA-A*0201-binding affinity

Journal of Immunology

Volumn 167, Issue 2, 2001, Pages 787-796

  Keogh, E ^a   Fikes, J ^a   Southwood, S ^a   Celis, E ^a   Chesnut, R ^a   Sette, A ^a  

^a Epimmune   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; EPITOPE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA A ANTIGEN; INTERLEUKIN 4; PROTEIN P53; TUMOR ANTIGEN;

ALLELE; AMINO ACID SUBSTITUTION; ANTIGEN DETECTION; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ANTIGEN RECOGNITION; ARTICLE; BINDING AFFINITY; CANCER CELL CULTURE; DENDRITIC CELL; EPITOPE MAPPING; FEMALE; HLA MATCHING; HLA SYSTEM; HUMAN; HUMAN CELL; IC 50; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; MALE; NORMAL HUMAN; ONCOGENE NEU; PRIORITY JOURNAL;

EID: 0035879093     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.167.2.787     Document Type: Article

References (70)

1. A MAGE-6-encoded peptide is recognized by expanded lymphocytes infiltrating a spontaneously regressing human primary melanoma lesion
2. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection
3. Efficient tumor eradication by adoptively transferred cytotoxic T-cell clones in allogeneic hosts
4. Tumor eradication by wild-type p53-specific cytotoxic T lymphocytes
5. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression
6. Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen
7. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells
8. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma
9. Cancer immunotherapy: Synthetic and natural peptides in the balance
10. The makings of a tumor rejection antigen
11. Tumor antigens recognized by T lymphocytes
12. The multi-epitope approach for immunotherapy for cancer: Identification of several CTL epitopes from various tumor-associated antigens expressed on solid epithelial tumors
13. Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine
14. Identification of new HER2/neu-derived peptide epitopes that can elicit specific CTL against autologous and allogeneic carcinomas and melanomas
15. The humoral response to the tumor-suppressor gene-product p53 in human cancer: Implications for diagnosis and therapy
16. Dendritic cells and immune-based therapies
17. Presentation of exogenous protein antigens on major histocompatibility complex class I molecules by dendritic cells: Pathway of presentation and regulation by cytokines
18. Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: A phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease
19. Cellular and humoral immune responses in patients with metastatic renal cell carcinoma after vaccination with antigen pulsed dendritic cells
20. Identification of subdominant CTL epitopes of the GP100 melanoma-associated tumor antigen by primary in vitro immunization with peptide-pulsed dendritic cells
21. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines
22. Isolation of naturally processed peptides recognized by cytolytic T lymphocytes (CTL) on human melanoma cells in association with HLA-A2.1
23. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma
24. Peptide binding to the most frequent HLA-A class I alleles measured by quantitative molecular binding assays
25. Role of HLA-A motifs in identification of potential CTL epitopes in human papillomavirus type 16 E6 and E7 proteins
26. Targeting p53 as a general tumor antigen
27. Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes
28. Efficient MHC class I-peptide binding is required but does not ensure MHC class I-restricted immunogenicity
29. A newly identified MAGE-3-derived epitope recognized by HLA-A24-restricted cytotoxic T lymphocytes
30. HLA supertypes and supermotifs: A functional perspective on HLA polymorphism
31. Overlap in the repertoires of peptides bound in vivo by a group of related class I HLA-B allotypes
32. Binding of a peptide antigen to multiple HLA alleles allows definition of an A2-like supertype
33. Specificity and degeneracy in peptide binding to HLA-B7-like class I molecules
34. HLA-A2-binding peptides cross-react not only within the A2 subgroup but also with other HLA-A-locus allelic products
35. Several HLA alleles share overlapping peptide specificities
36. Practical, biochemical and evolutionary implications of the discovery of HLA class I supermotifs
37. The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes
38. Identification of A2-restricted hepatitis C virus-specific cytotoxic T lymphocyte epitopes from conserved regions of the viral genome
39. Degenerate and promiscuous recognition by CTL of peptides presented by the MHC class I A3-like superfamily: Implications for vaccine development
40. Human histocompatibility leukocyte antigen-binding supermotifs predict broadly cross-reactive cytotoxic T lymphocyte responses in patients with acute hepatitis
41. Degenerate cytotoxic T cell epitopes from P. falciparum restricted by multiple HLA-A and HLA-B supertype alleles
42. + T cells in hepatitis C virus-exposed healthy seronegative donors
43. Carcinoembryonic antigen gene family: Molecular biology and clinical perspectives
44. Structure, chromosomal localization, and expression of 12 genes of the MAGE family
45. Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor
46. The p53 tumor suppressor gene
47. Accumulation of the p53 protein allows recognition by human CTL of a wild-type p53 epitope presented by breast carcinomas and melanomas
48. Generation of cytotoxic T-cell responses with synthetic melanoma-associated peptides in vivo: Implications for tumor vaccines with melanoma-associated antigens
49. Autologous human dendriphages pulsed with synthetic or natural tumor peptides elicit tumor-specific CTLs in vitro
50. Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes
51. Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules
52. Enhanced in vitro potency and in vivo immunogenicity of a CTL epitope from hepatitis C virus core protein following amino acid replacement at secondary HLA-A2.1 binding positions
53. Peptide vaccination with an anchor-replaced CTL epitope protects against human papillomavirus type 16-induced tumors expressing the wild-type epitope
54. Recombinant virus vaccination against "self" antigens using anchor-fixed immunogens
55. Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues
56. Review: The use of synthetic peptides to characterize CTL responses in acute and chronic viral diseases
57. In vitro immunization and expansion of antigen-specific cytotoxic T lymphocytes for adoptive immunotherapy using peptide-pulsed dendritic cells
58. Production of human cells expressing individual transferred HLA-A,-B,-C genes using an HLA-A,-B,-C null human cell line
59. Presence on a human melanoma of multiple antigens recognized by autologous CTL
60. A breast and melanoma-shared tumor antigen: T cell responses to antigenic peptides translated from different open reading frames
61. T cells from tumor-immune mice nonspecifically expanded in vitro with anti-CD3 plus IL-2 retain specific function in vitro and can eradicate disseminated leukemia in vivo
62. p53, a potential target for tumor-directed T cells
63. Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines
64. A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3
65. + T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes
66. Immunogenicity of peptides bound to MHC class I molecules depends on the MHC-peptide complex stability
67. Discrete proteolytic intermediates in the MHC class I antigen processing pathway and MHC I-dependent peptide trimming in the ER
68. Structure of peptides associated with class I and class II MHC molecules
69. Selective expansion of high- or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy
70. Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses